Form 4: Immix Biopharma CEO Ilya Rachman Reports Acquisition of Shares Following Merger

Ilya Rachman, CEO and Chairman of Immix Biopharma, reports acquiring 218,359 shares of common stock due to a merger with Nexcella, Inc.

Summary

• On May 20, 2024, Ilya Rachman, the CEO and Chairman of Immix Biopharma, acquired 218,359 shares of Immix Biopharma common stock.
• This acquisition resulted in Mr. Rachman beneficially owning 1,130,359 shares of Immix Biopharma common stock.
• The shares were received in exchange for shares of common stock of Nexcella, Inc., which merged with Immix Biopharma on May 20, 2024, with Immix Biopharma as the surviving entity.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is a standard SEC filing reporting a change in beneficial ownership due to a merger. It doesn't inherently indicate positive or negative sentiment, but rather a factual disclosure.

Positives

• The merger with Nexcella, Inc. has resulted in an increase in Ilya Rachman's holdings of Immix Biopharma stock, potentially signaling confidence in the company's future.

Industry Context

Mergers and acquisitions are common in the biopharmaceutical industry as companies seek to expand their pipelines, acquire new technologies, or achieve synergies.

Stakeholder Impact

• The merger and subsequent increase in insider ownership could be viewed positively by shareholders, potentially increasing confidence in the company's direction.

Key Dates